SYK earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 35.42. Updated 2026-07-23.
Stryker (SYK) Research Hub
Stryker (SYK) trades on NYSE, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 275.56 USD (+0.06%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 35.42, market cap 119.19B. This hub links to the full technical, earnings and options research available for SYK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NYSE, US |
| Last close | 275.56 USD (+0.06%) |
| 52-week range | 267 USD – 352.49 USD |
| Trend regime | Range |
| 14-day RSI | 19.2 (Oversold) |
| Trailing P/E | 35.42 |
| Market cap | 119.19B |
| Dividend yield | 1.13% |
| Next earnings | 2026-07-30 |
Available research for SYK
Covered Call on SYK: how it works, illustrative setup around the real 275.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SYK: how it works, illustrative setup around the real 275.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SYK: how it works, illustrative setup around the real 275.56 USD price, max profit/loss, breakeven and when to use it. Educational.
SYK technical analysis: range, last 275.56 USD, RSI 19.2, 52w range 267 USD–352.49 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SYK in?
Stryker (SYK) is classified under Healthcare (Medical - Devices), listed on NYSE, US.
Is SYK in an uptrend or downtrend?
As of 2026-09-11, SYK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SYK's trailing P/E ratio?
SYK's trailing P/E is 35.42, with a market cap of 119.19B. See the earnings research page for full valuation detail.
When does SYK next report earnings?
SYK is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 3.49 USD.